UV light damages the DNA of skin cells, which can lead to skin cancer. But this process is counteracted by the DNA repair machinery, acting as a molecular sunscreen. It has been unclear, however, how repair proteins work on DNA tightly packed in chromatin, where access to DNA damage is restricted by protein packaging. Using cryo electron microscopy, researchers from the Thomä group at the Friedrich Miescher Institute for Biomedical Research (FMI) have identified a new mechanism whereby repair proteins detect and bind to damaged DNA that is densely packed in nucleosomes.
Ultraviolet (UV) light damages DNA, producing small lesions. These UV lesions are first detected by a protein complex known as UV-DDB and - once the lesions have been identified - the rest of the DNA repair machinery swings into action.
The question is, how can UV-DDB bind to lesions when the DNA is coiled around the histone protein core of the so-called nucleosome (the basic unit of chromatin - the DNA packaging of eukaryotic chromosomes)?
To gain access, UV-DDB was previously thought to require the assistance of additional proteins that shift the nucleosome. Researchers from the group led by Nicolas Thomä have now found that additional proteins are not necessarily needed to detect UV-induced lesions; instead, the UV-DDB complex takes advantage of the intrinsic dynamics of nucleosomal DNA. The DNA repair factor appears to catch the UV lesions when they are temporarily accessible.
In their study published in Nature, the scientists determined various three dimensional (3D) structures of UV-DDB bound to lesions at different locations around the nucleosome, using cryo-electron microscopy - a technique that allows the 3D structure of biomolecules to be visualized with atomic detail.
The researchers concluded that damage detection strategies depend on where the DNA lesion is located. In the case of "accessible" lesions, which can be directly contacted, UV-DDB binds to the lesion tightly. The recognition of "occluded" lesions (facing the histone protein core of the nucleosome) requires additional steps: UV-DDB binds the UV lesions when they are exposed temporarily through the natural dynamics of the nucleosome.
One of the lead authors, Syota Matsumoto, explains: "To visualize what happens at the molecular level, imagine a piece of string wrapped around a spool, which becomes accessible when it is pulled forwards or backwards a little bit."
The researchers called the mechanism of DNA damage read-out "slide-assisted site-exposure". This new mechanism operates independently of chromatin remodelers and does not require chemical energy to slide or dislodge nucleosomes.
Thomä comments: "In the past, nucleosomes were thought to be a major obstacle for DNA-binding proteins. In our study, we show that they are not, and that the system is tailored to bind UV lesions wherever they are.
What makes this study really powerful is the fact that the mechanism we identified could very well be used by many other types of DNA-binding proteins. Accessing nucleosomal DNA is not only fundamental for DNA repair, but is relevant for all proteins that bind to chromatin. With our study, we define a previously unknown strategy for protein access to chromatinized DNA templates."
Syota Matsumoto*, Simone Cavadini*, Richard D. Bunker*, Ralph S. Grand, Alessandro Potenza, Julius Rabl, Junpei Yamamoto, Andreas D. Schenk, Dirk Schübeler, Shigenori Iwai, Kaoru Sugasawa, Hitoshi Kurumizaka, Nicolas H. Thomä (2019) DNA damage detection in nucleosomes involves DNA register shifting. Nature, published online on May 29, 2019
*these authors contributed equally.
Dr Nicolas Thomä, email@example.com, Tel: + 41 (0)61 697 86 30
Nicolas Thomä is a Senior Group Leader at the FMI. With his research group he is interested in the machinery that controls the integrity of the DNA. The researchers combine X-ray crystallography and cryo-electron microscopy with biochemical and biophysical studies to better understand large protein complexes involved in crucial cellular functions such as DNA repair, telomere maintenance and epigenetics in health and disease.
About the FMI
The Friedrich Miescher Institute for Biomedical Research (FMI), based in Basel, Switzerland, is a world-class biomedical research institute dedicated to understanding the molecular mechanisms of health and disease. Its main areas of expertise are neurobiology, quantitative biology and epigenetics. With a staff of about 350, the FMI offers an exceptional training environment for PhD students and postdoctoral fellows from around the world. The FMI is affiliated with the University of Basel and the Novartis Institutes for BioMedical Research, and is currently being co-led by Silvia Arber and Dirk Schübeler.
Isabelle Baumann | EurekAlert!
Why developing nerve cells can take a wrong turn
04.06.2020 | Universität zu Köln
Innocent and highly oxidizing
04.06.2020 | Albert-Ludwigs-Universität Freiburg im Breisgau
In meningococci, the RNA-binding protein ProQ plays a major role. Together with RNA molecules, it regulates processes that are important for pathogenic properties of the bacteria.
Meningococci are bacteria that can cause life-threatening meningitis and sepsis. These pathogens use a small protein with a large impact: The RNA-binding...
An analysis of more than 200,000 spiral galaxies has revealed unexpected links between spin directions of galaxies, and the structure formed by these links...
Two prominent X-ray emission lines of highly charged iron have puzzled astrophysicists for decades: their measured and calculated brightness ratios always disagree. This hinders good determinations of plasma temperatures and densities. New, careful high-precision measurements, together with top-level calculations now exclude all hitherto proposed explanations for this discrepancy, and thus deepen the problem.
Hot astrophysical plasmas fill the intergalactic space, and brightly shine in stellar coronae, active galactic nuclei, and supernova remnants. They contain...
In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".
Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...
Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.
researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
04.06.2020 | Life Sciences
04.06.2020 | Physics and Astronomy
04.06.2020 | Life Sciences